North America will lead sales growth for GLP-1 receptor agonists

Market sales in US$ for GLP-1 receptor agonists in obesity and diabetes by regional market (2023 vs 2033 projections)

$47.5M
$4.3B
$7B
$741.9M
$542.6M
$26.6B
$334M
$23.3B
$25.3B
$3B
$2.2B
$114B
2023
2033
Africa
APAC
Europe
LATAM
Middle East
North America
Data first published May 2024.
Source: Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast. GlobalData. Get the dataCreated with Datawrapper